超声造影引导经皮经肝胆管引流术对恶性胆道梗阻合并3期慢性肾病患者安全有效
本研究回顾性纳入2019年1月至2023年12月接受超声造影引导经皮经肝胆管引流术(CEUS-PTCD)的634例患者,最终分析66例恶性胆道梗阻合并3期慢性肾病(CKD3)患者。结果显示所有患者均成功实现外引流,术中及术后无显著并发症,术后血清胆红素及肝酶水平较术前显著下降(P值均小于0.05),而估算肾小球滤过率(eGFR)术前术后无统计学显著变化(P=0.295)。结论认为CEUS-PTCD对恶性胆道梗阻合并CKD3患者是安全有效的胆道引流方法。
要点
- CEUS-PTCD在恶性胆道梗阻合并CKD3患者中全部成功实现外引流,术中术后无显著并发症。
- 术后血清胆红素及肝酶较术前显著下降(P值均小于0.05),eGFR无统计学显著变化(P=0.295)。
- 23例(34.8%)患者胆管最大扩张直径≤4 mm,5例(7.6%)存在少量腹水。
核心结论
- CEUS-PTCD是恶性胆道梗阻合并CKD3患者安全有效的胆道引流方法。
研究设计与样本
- 回顾性研究,2019年1月至2023年12月共634例接受CEUS-PTCD的患者,最终纳入66例恶性胆道梗阻合并CKD3患者(中位年龄66岁,范围30-89岁,男46例、女20例)。
关键影像表现/征象
- 23例(34.8%)患者胆管最大扩张直径≤4 mm。
- 5例(7.6%)患者存在少量腹水。
- 24例(36.4%)患者超声造影剂进入胆管及血流。
临床应用与阅片要点
- 术后血清胆红素及肝酶较术前显著下降(P值均小于0.05)。
- eGFR术前术后无统计学显著变化(P=0.295),造影剂进入血流组与未进入血流组之间比较P=0.254。
- 所有患者均成功实现外引流,术中及术后无显著并发症。
局限性
- 本研究为回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study aimed to validate the efficacy and safety of contrast-enhanced ultrasound-guided percutaneous transhepatic cholangiodrainage (CEUS-PTCD) as a biliary drainage procedure in patients with malignant biliary obstruction and stage 3 chronic kidney disease (CKD3).
MATERIALS AND METHODS: Between January 2019 and December 2023, 634 patients who underwent CEUS-PTCD were retrospectively enrolled in this study. During the procedure, imaging parameters such as the maximum diameter of the dilated bile duct, presence of ascites, detailed findings from CEUS, and clinical outcomes were meticulously recorded. Laboratory results, including serum bilirubin levels, liver function tests, and estimated glomerular filtration rate (eGFR), were evaluated in one day before and three days after procedure. The aforementioned parameters were compared using the paired-sample t test and the Wilcoxon test.
RESULTS: A total of 66 (10.41 %) patients with malignant biliary obstruction and CKD3 were included in the final analysis (median age: 66, range: 30-89 years, 46 males and 20 females). Procedure records indicated that 23 patients (34.8 %) had a maximum biliary duct dilation diameter of ≤ 4 mm, while 5 patients (7.6 %) exhibited mild ascites. Additionally, 24 patients (36.4 %) had ultrasound contrast agent entry into both the biliary duct and bloodstream. All patients successfully achieved external bile drainage following CEUS-PTCD, with no significant complications observed during or after the intervention. Post-procedure, there was a statistically significant reduction in all previously elevated serum bilirubin and liver enzyme levels (P-values were less than 0.05). Furthermore, no statistically significant alterations in eGFR were observed prior to or following CEUS-PTCD across all patients (P = 0.295), including comparisons between groups with and without the ultrasound contrast agent into the bloodstream (P = 0.254).
CONCLUSION: CEUS-PTCD is a safe and effective biliary drainage procedure for patients with malignant biliary obstruction and CKD3.
引用
- Zheng Q, Ou D, Xie F, et al. Contrast-enhanced ultrasound-guided percutaneous transhepatic cholangiodrainage is a safe and effective procedure for patients with malignant biliary obstruction and stage 3 chronic kidney disease. Eur J Radiol. 2024. PMID: 39342886. doi:10.1016/j.ejrad.2024.111761
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。